SEC Form 4 · accession 0001209191-16-156837
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy L. Moore
Officer — EVP, Technical Operations
Period of report
Dec 22, 2016
Accepted (ET)
Dec 27, 2016 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 22, 2016 | A | 8,400 | $0.00 | A | 58,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $46.09 | Dec 22, 2016 | A | 30,700 | A | — | Dec 22, 2026 | Common Stock | 30,700 | 30,700 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.